CIR during follow-up, according to MRD conversion (from MRD⁻to MRD⁺) and defined MRD cutoffs in BM and PB. (A) CIR of 25 patients with MRD conversion in BM. (B) CIR of 64 patients according to the MRD cutoff exceeding 150 RUNX1-RUNX1T1 TL/10⁶B2M copies in at least 1 BM follow-up sample obtained in the posttreatment period. (C) CIR of 25 patients with MRD conversion in PB. (D) CIR of 39 patients according to MRD cutoff exceeding 50 RUNX1-RUNX1T1 TL/10⁶B2M copies in at least 1 PB follow-up sample obtained in the posttreatment period. Time to relapse is calculated from the first sample, with a RUNX1-RUNX1T1 TL >150 (BM) or >50 (PB) RUNX1-RUNX1T1 TL/10⁶B2M copies up to relapse and, in cases not exceeding these thresholds, from the first sample with increasing MRD level.